New shot cuts migraine days by half in chinese trial

NCT ID NCT05458011

Completed Disease control Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called fremanezumab, given as a shot under the skin, to prevent migraines in 365 Chinese adults. Participants received either monthly or quarterly injections or a placebo for 12 weeks, followed by an open-label period. The main goal was to see if the drug reduced the number of migraine days per month. The trial was completed and showed that fremanezumab helped lower migraine frequency.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Teva Investigational Site 88001

Beijing, 100853, China
Teva Investigational Site 88003

Chengdu, 610041, China
Teva Investigational Site 88004

Beijing, 100044, China
Teva Investigational Site 88005

Luoyang, 4710039, China
Teva Investigational Site 88006

Wuhan, 430071, China
Teva Investigational Site 88008

Changchun, 130021, China
Teva Investigational Site 88009

Changchun, 130041, China
Teva Investigational Site 88010

Lianyungang, 222002, China
Teva Investigational Site 88011

Shijiazhuang, 50073, China
Teva Investigational Site 88012

Wuhan, 430030, China
Teva Investigational Site 88013

Guiyang, 550004, China
Teva Investigational Site 88015

Suzhou, 215004, China
Teva Investigational Site 88016

Shenyang, 110016, China
Teva Investigational Site 88017

Wenzhou, 325000, China
Teva Investigational Site 88019

Fuzhou, 350001, China
Teva Investigational Site 88020

Guangzhou, 510260, China
Teva Investigational Site 88021

Shanghaishi, 200040, China
Teva Investigational Site 88022

Changsha Shi, 410008, China
Teva Investigational Site 88023

Tianjin, 300120, China
Teva Investigational Site 88024

Tianjin, 300052, China
Teva Investigational Site 88025

Shanghaishi, 200120, China
Teva Investigational Site 88026

Harbin, 150001, China
Teva Investigational Site 88028

Baotou Shi, 014060, China
Teva Investigational Site 88029

Chongqing, 400700, China
Teva Investigational Site 88030

Changsha Shi, 410013, China
Teva Investigational Site 88031

Zhanjiang, 524008, China
Teva Investigational Site 88032

Xining, 810007, China
Teva Investigational Site 88033

Rizhao, 276800, China
Teva Investigational Site 88034

Zhengzhou, 450003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.